Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Myelofibrosis (MF)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Testing effectiveness (Phase 2)Study completedNCT01644110
What this trial is testing

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPMF+3 more
University of Ulm 96
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001
What this trial is testing

A Safety and Tolerability Study of Jaktinib

Who this might be right for
Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Early research (Phase 1)WithdrawnNCT05115344
What this trial is testing

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Who this might be right for
Myeloproliferative Neoplasm (MPN)Myelofibrosis，MF
Guizhou Bailing Group Pharmaceutical Co Ltd
Testing effectiveness (Phase 2)Study completedNCT00494585
What this trial is testing

CEP-701 for PH-negative Myelofibrosis

Who this might be right for
LeukemiaMyelofibrosis
M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Study completedNCT01224496
What this trial is testing

Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders

Who this might be right for
Myelodysplastic Syndrome (MDS)Aplastic Anaemia (AA)Myelofibrosis (MF)+1 more
Singapore General Hospital 38
Testing effectiveness (Phase 2)Looking for participantsNCT06887803
What this trial is testing

Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Who this might be right for
Myelofibrosis (MF)
iOnctura 26
Large-scale testing (Phase 3)Looking for participantsNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Early research (Phase 1)Looking for participantsNCT07802405
What this trial is testing

Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
MF With Splenomegaly
Henan Cancer Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT05280509
What this trial is testing

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Who this might be right for
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc. 70
Testing effectiveness (Phase 2)Ended earlyNCT02711137
What this trial is testing

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumors
Incyte Corporation 137
Large-scale testing (Phase 3)Not Yet RecruitingNCT07539779
What this trial is testing

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Who this might be right for
LuspaterceptPoor Erythroid EngraftmentHematological Malignancies+1 more
Nanfang Hospital, Southern Medical University 196
Early research (Phase 1)Looking for participantsNCT06343805
What this trial is testing

LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Who this might be right for
Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company 256
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02098161
What this trial is testing

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

Who this might be right for
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT01445769
What this trial is testing

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Incyte Corporation 45
Testing effectiveness (Phase 2)Study completedNCT00606307
What this trial is testing

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Who this might be right for
Myeloproliferative Diseases
Italfarmaco 29
Testing effectiveness (Phase 2)Looking for participantsNCT07443306
What this trial is testing

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis

Who this might be right for
MF
Chengdu Zenitar Biomedical Technology Co., Ltd 64
Post-approval studies (Phase 4)Active Not RecruitingNCT02386800
What this trial is testing

CINC424A2X01B Rollover Protocol

Who this might be right for
Primary MyelofibrosisPolycythemia VeraGraft Versus Host Disease+2 more
Novartis Pharmaceuticals 279
Next Page